Vnitr Lek 2025, 71(1):14-17 | DOI: 10.36290/vnl.2025.002

Hyperuricaemia and kidneys

Brenda Mercy Musungu¹, Marie Vaňková¹, Kateřina Oulehle¹, Oskar Zakiyanov², Jan Vachek^{1, 2}, Vladimír Tesař²

¹ Interní oddělení s hemodialyzačním střediskem, Klatovská nemocnice, a. s.

² Klinika nefrologie 1. LF UK a VFN v Praze

Hyperuricaemia occurs in 60% of patients with chronic kidney disease (CKD) and gout in about 25% of these patients. Despite the frequent co-occurrence, the influence of uric acid on the progression of kidney disease is not clearly understood. There is controversy over the indications for treatment of asymptomatic uricemia in patients with CKD. The preponderance of evidence suggests that asymptomatic hyperuricaemia is likely to be harmful, but may be particularly relevant to certain subgroups of patients, namely those with systemic crystal deposits, urate crystalluria or urolithiasis, and those with high intracellular uric acid levels. Current evidence does not support the deployment of xanthine oxidase inhibitors to ameliorate the progression of CKD in patients with asymptomatic hyperuricaemia.

Keywords: uric acid, hyperuricemia, chronic kidney disease (CKD), xanthine oxidase inhibitors, gout.

Accepted: February 6, 2025; Published: February 18, 2025  Show citation